We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

CHEMBIO DIAGNOSTIC SYSTEMS

Chembio develops, manufactures and commercializes diagnostic solutions and products for the rapid and early detection... read more Featured Products: More products

Download Mobile App





Chembio Diagnostics Showcases New DPP Line of Rapid Tests at MEDICA 2019

By LabMedica International staff writers
Posted on 19 Nov 2019
Print article
Image: DPP® Syphilis Screen & Confirm Assay (Photo courtesy of Chembio Diagnostics)
Image: DPP® Syphilis Screen & Confirm Assay (Photo courtesy of Chembio Diagnostics)
Chembio Diagnostics (Medford, NY, USA) showcased its new DPP line of rapid tests, including DPP Syphilis Screen and Confirm; DPP HIV 1-2 Screen; and, for the global market, DPP Syphilis/HIV combo, the MEDICA 2019 International Trade Fair on November 18-21 in Düsseldorf, Germany. In addition, the company presented its legacy product line of HIV 1-2 SURE CHECK, HIV 1-2 STAT-PAK, HIV 1-2 STAT-PAK Dipstick, as well as its line of unique animal TB diagnostic products.

The MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals. The event drew over 6,000 exhibitors from 70 countries and 120,000 trade visitors from over 170 countries.

Chembio is a leading Point-of-Care (POC) diagnostics company that focuses on detecting and diagnosing infectious diseases. The company’s patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes.

At the 2019 edition of MEDICA, Chembio showcased its DPP Syphilis Screen and Confirm Assay (CE Marked), a rapid POC test that simultaneously and separately detects treponemal and nontreponemal antibodies. Since it screens and confirms syphilis infection simultaneously, there is no need for reflex testing and it does not require specialized medical training. It provides results in as little as 15 minutes, enabling physicians to make treatment decisions, while reducing overtreatment rate and cost burden by eliminating repeated visits to healthcare professionals.

Chembio also showcased its DPP HIV 1-2 Screen Assay, a CLIA-waived test for the rapid detection of HIV 1 and HIV 2 antibodies in oral fluid and all blood matrices. It is intended for use as a POC test to aid in the diagnosis of infection with HIV 1 and HIV 2 and is suitable for use in multi-test algorithms that have been established in many countries or as a standalone initial test. For the global market, Chembio showcased its DPP Syphilis/HIV Combo Assay, the first dual HIV 1/2 and Syphilis POC test based on its DPP technology platform. It is a single-use, immunochromatographic, rapid test for the detection of antibodies to Human Immunodeficiency Virus Types 1 and 2 (HIV 1/2) and Treponema pallidum (the causative agent of syphilis) in fingerstick whole blood, venous whole blood, serum, and plasma. A unique feature of this kit is Chembio’s new DPP SampleTainer bottle which contains a pre-measured dilution buffer within a closed vial that also serves as a dropper for performing the assay.

In addition, Chembio showcased its legacy product line, including HIV 1-2 SURE CHECK, a unique, easy-to-use, self-contained, single-use collection and testing device for the rapid, visual detection of antibodies to HIV 1 and HIV 2; HIV 1-2 STAT-PAK, which are easy-to-perform, single-use diagnostic tests for the rapid (15 minutes), visual detection of antibodies to HIV 1 and HIV 2 at POC; and HIV 1-2 STAT-PAK Dipstick, which are easy-to-perform, single-use diagnostic tests for the rapid, visual detection of antibodies to HIV 1 and HIV 2.

Related Links:
Chembio Diagnostics

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.